Implantable cardioverter defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, or no structural heart disease
References (29)
- et al.
Prognosis of patients with ventricular tachycardia and ventricular fibrillation: role of the underlying etiology
J Am Coll Cardiol
(1988) - et al.
Long-term follow-up after sustained monomorphic ventricular tachycardia: causes, pump failure, and empiric antiarrhythmic therapy that modify survival
Am Heart J
(1991) - et al.
Repetitive paroxysmal ventricular tachycardia and sudden death in a child
Am J Cardiol
(1984) - et al.
Idiopathic ventricular fibrillation
Am Heart J
(1990) - et al.
Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy
J Am Coll Cardiol
(1993) - et al.
Guidelines for the use of implantable cardioverter defibrillators
Eur Heart J
(1992) - et al.
Right ventricular dysplasia: a report of 24 cases
Circulation
(1982) - et al.
The arrhythmogenic right ventricle
- et al.
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease: results in patients with inducible and noninducible ventricular tachycardia
Circulation
(1992) - et al.
Catheter ablation of idiopathic right ventricular tachycardia [Editorial comment]
Circulation
(1990)
A long-term follow up of 15 patients with arrhythmogenic right ventricular dysplasia
Eur Heart J
Long-term follow-up in patients with arrhythmogenic right ventricular disease
Eur Heart J
Right ventricular cardiomyopathy and sudden death in young people
N Engl J Med
Long-term follow-up in patients with arrhythmogenic right ventricular disease [Abstract]
Circulation
Cited by (75)
Long-term right ventricular implantable cardioverter-defibrillator lead performance in arrhythmogenic right ventricular cardiomyopathy
2016, Heart RhythmCitation Excerpt :Therefore, long-term optimum lead performance is imperative to patient safety5,6 and is of particular importance in patients with progressive diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) because the majority of these patients will undergo ICD placement at a relatively young age. Progressive replacement of muscle with fibrofatty deposits may result in loss of R-wave amplitude and suboptimal sensing.7 Furthermore, ARVC patients are often diagnosed when they are young adults, with a longer course of disease progression compared to other conditions for which ICDs are implanted at later stages in life.
Implantable Cardioverter Defibrillator in Arrhythmogenic Cardiomyopathy
2011, Cardiac Electrophysiology ClinicsCitation Excerpt :The first studies aimed at defining the clinical results of ICD implantation were conducted on small cohorts of AC patients.19–21 In 1994 Breithardt and colleagues19 reported 18 patients with AC who received an ICD because of drug refractory VT or VF, or previous cardiac arrest without reproducible induction of VT or VF. Only the initial patient received an epicardial lead system, whereas in the subsequent 17 patients a transvenous approach was used.
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Risk Stratification and Therapy
2008, Progress in Cardiovascular DiseasesCitation Excerpt :However, EPS may provide useful information if the spontaneous VT cycle length was not recorded. In summary, the available data suggest that young age (<35 years), prior cardiac arrest, fast and poorly tolerated VT with different morphologies, syncope, severe right ventricular dysfunction, heart failure with left ventricular involvement, familial occurrence of juvenile sudden death are the major determinants in predicting sudden death and worse outcome.4-8,16-24,31,32 In patients with ARVC/D, vigorous or competitive sport activities should be restricted to decrease the rate of structural and/or functional progression of the disease as well as the risk of arrhythmic death.
The Value of Strain Echocardiography in Predicting Electrical Progression in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy
2023, Texas Heart Institute JournalArrhythmogenic cardiomyopathy
2019, Zdravniski Vestnik